Replies to post #188840 on Biotech Values

[DewDiligence]

Tobira/RGDO cited (along with CNAT, GLMD and others) in Medscape overview of NASH therapeutics:

http://www.medscape.com/viewarticle/841001_7

H/t ‘staccani’.

[DewDiligence]

Tobira/RGDO’s presentations at EASL:

http://finance.yahoo.com/news/tobira-therapeutics-highlights-presentations-international-120000903.html

• Abstract number RS-2026 (oral presentation, April 23, 4:15 PM)
CCR2+ infiltrating monocytes promote acetaminophen-induced actue liver injury – therapeutic implications of inhibiting CCR2 and CCL2
O. Krenkel; J. Mossanen; C. Ergen; F. Heymann; E. Lefebvre; D. Eulberg; C. Trautwein; F. Tacke

• Abstract number P0906 (poster session, April 24, 1:00 PM)
Inhibition of HCV replication by CCR5 blockade with cenicriviroc and maraviroc
K. Sherman; L. Kong; J. Blackard

• Abstract number P0146 (poster session, April 25, 10:00 AM)
Oral, once-daily, cenicriviroc leads to rapid and potent CCR2 and CCR5 blockade in subjects with advanced liver disease, similar to effects seen in healthy volunteers and HIV-1 infected subjects
N. Utay; M. Gottwald; W. Change; M. Willett; E. Lefebvre